Novan is a privately-held, clinical stage biotechnology company advancing potentially best-in-class therapies using drugable nitric oxide. The company's patented Nitricil™ technology overcomes the previous delivery issues with nitric oxide by stably storing the gaseous species as a solid that can be transformed into targeted therapeutics.